STOCKSCREENR
Log In

DRMA

NASDAQ

Dermata Therapeutics, Inc.

$1.22+0.02(+1.67%)Mkt Cap: $831.50K

Key Stats

Market Cap

$831.50K

P/E Ratio

0.08

EPS

$15.49

Dividend Yield

0.00%

52-Week Range

$1.11 — $23.70

Volume

50.65K

Avg Volume

2.18M

Beta

0.60

Valuation

P/E (TTM)

0.08

Forward P/E

—

PEG Ratio

-0.00

P/S (TTM)

0.00

P/B (TTM)

0.31

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-1.92%

ROA (TTM)

-1.74%

ROIC

—

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

—

Debt/Equity

0.00

Current Ratio

4.56

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-0.33%

EPS Growth (5Y)

-1.79%

Sales Growth (3Y)

+0.00%

Sales Growth (5Y)

+0.00%

EPS Est (This Year)

$-3.01

EPS Est (Next Year)

—

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$4.54

Analyst Consensus

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

0

Outstanding Shares

681.56K

Float

498.53K

Free Float %

73.15%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2021-08-13

Employees

8

CEO

Gerald T. Proehl

Index Membership

—

Website

https://www.dermatarx.com

Dermata Therapeutics, Inc. (DRMA) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $831.50K, a P/E ratio of 0.08, DRMA is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare DRMA against other stocks using dozens of fundamental and technical filters.

Similar Stocks

IBO.V

Universal Ibogaine Inc.

$0.01

-50.00%

$1.56M

ASBP

Aspire Biopharma Holdings, Inc.

$0.88

-10.21%

$3.03M

BRTX

BioRestorative Therapies, Inc.

$0.25

-12.40%

$2.24M

CARM

Carisma Therapeutics, Inc.

$0.04

+2.70%

$1.59M

INM

InMed Pharmaceuticals Inc.

$0.89

+3.30%

$1.61M

VRAX

Virax Biolabs Group Limited

$0.20

+8.74%

$880.11K

Frequently Asked Questions

What is Dermata Therapeutics, Inc.'s P/E ratio?

Dermata Therapeutics, Inc. (DRMA) has a trailing twelve-month (TTM) P/E ratio of 0.08. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Dermata Therapeutics, Inc. pay a dividend?

No, Dermata Therapeutics, Inc. (DRMA) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Dermata Therapeutics, Inc.'s market cap?

Dermata Therapeutics, Inc. (DRMA) has a market capitalization of $831,500, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.